White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation

Charlotte E. Teunissen, Markus Otto, Sebastiaan Engelborghs, Sanna-Kaisa Herukka, Sylvain Lehmann, Piotr Lewczuk, Alberto Lleó, Armand Perret-Liaudet, Hayrettin Tumani, Martin R. Turner, Marcel M. Verbeek, Jens Wiltfang, Henrik Zetterberg, Lucilla Parnetti, Kaj Blennow

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer's disease cerebrospinal fluid (CSF) biomarkers, anti-neuromyelitis optica antibodies and blood neurofilament light. We still, however, have a strong need for additional biomarkers and several gaps in their development and implementation should be filled. Examples of such gaps are i) limited knowledge of the causes of neurological diseases, and thus hypotheses about the best biomarkers to detect subclinical stages of these diseases; ii) the limited success translating discoveries obtained by e.g. initial mass spectrometry proteomic low-throughput studies into immunoassays for widespread clinical implementation; iii) lack of interaction among all stakeholders to optimise and adapt study designs throughout the biomarker development process to medical needs, which may change during the long period needed for biomarker development. The Society for CSF Analysis and Clinical Neurochemistry (established in 2015) has been founded as a concerted follow-up of large standardisation projects, including BIOMARKAPD and SOPHIA, and the BioMS-consortium. The main aims of the CSF society are to exchange high level international scientific experience, to facilitate the incorporation of CSF diagnostics into clinical practice and to give advice on inclusion of CSF analysis into clinical guidelines. The society has a broad scope, as its vision is that the gaps in development and implementation of biomarkers are shared among almost all neurological diseases and thus they can benefit from the activities of the society.
Original languageEnglish
Article number30
JournalAlzheimer's Research and Therapy
Volume10
Issue number1
DOIs
Publication statusPublished - 2018

Cite this

Teunissen, Charlotte E. ; Otto, Markus ; Engelborghs, Sebastiaan ; Herukka, Sanna-Kaisa ; Lehmann, Sylvain ; Lewczuk, Piotr ; Lleó, Alberto ; Perret-Liaudet, Armand ; Tumani, Hayrettin ; Turner, Martin R. ; Verbeek, Marcel M. ; Wiltfang, Jens ; Zetterberg, Henrik ; Parnetti, Lucilla ; Blennow, Kaj. / White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. In: Alzheimer's Research and Therapy. 2018 ; Vol. 10, No. 1.
@article{1e6039a0a62a46acb408d94615c7d4ab,
title = "White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation",
abstract = "Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer's disease cerebrospinal fluid (CSF) biomarkers, anti-neuromyelitis optica antibodies and blood neurofilament light. We still, however, have a strong need for additional biomarkers and several gaps in their development and implementation should be filled. Examples of such gaps are i) limited knowledge of the causes of neurological diseases, and thus hypotheses about the best biomarkers to detect subclinical stages of these diseases; ii) the limited success translating discoveries obtained by e.g. initial mass spectrometry proteomic low-throughput studies into immunoassays for widespread clinical implementation; iii) lack of interaction among all stakeholders to optimise and adapt study designs throughout the biomarker development process to medical needs, which may change during the long period needed for biomarker development. The Society for CSF Analysis and Clinical Neurochemistry (established in 2015) has been founded as a concerted follow-up of large standardisation projects, including BIOMARKAPD and SOPHIA, and the BioMS-consortium. The main aims of the CSF society are to exchange high level international scientific experience, to facilitate the incorporation of CSF diagnostics into clinical practice and to give advice on inclusion of CSF analysis into clinical guidelines. The society has a broad scope, as its vision is that the gaps in development and implementation of biomarkers are shared among almost all neurological diseases and thus they can benefit from the activities of the society.",
author = "Teunissen, {Charlotte E.} and Markus Otto and Sebastiaan Engelborghs and Sanna-Kaisa Herukka and Sylvain Lehmann and Piotr Lewczuk and Alberto Lle{\'o} and Armand Perret-Liaudet and Hayrettin Tumani and Turner, {Martin R.} and Verbeek, {Marcel M.} and Jens Wiltfang and Henrik Zetterberg and Lucilla Parnetti and Kaj Blennow",
year = "2018",
doi = "10.1186/s13195-018-0359-x",
language = "English",
volume = "10",
journal = "Alzheimer's Research & Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

Teunissen, CE, Otto, M, Engelborghs, S, Herukka, S-K, Lehmann, S, Lewczuk, P, Lleó, A, Perret-Liaudet, A, Tumani, H, Turner, MR, Verbeek, MM, Wiltfang, J, Zetterberg, H, Parnetti, L & Blennow, K 2018, 'White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation' Alzheimer's Research and Therapy, vol. 10, no. 1, 30. https://doi.org/10.1186/s13195-018-0359-x

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. / Teunissen, Charlotte E.; Otto, Markus; Engelborghs, Sebastiaan; Herukka, Sanna-Kaisa; Lehmann, Sylvain; Lewczuk, Piotr; Lleó, Alberto; Perret-Liaudet, Armand; Tumani, Hayrettin; Turner, Martin R.; Verbeek, Marcel M.; Wiltfang, Jens; Zetterberg, Henrik; Parnetti, Lucilla; Blennow, Kaj.

In: Alzheimer's Research and Therapy, Vol. 10, No. 1, 30, 2018.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation

AU - Teunissen, Charlotte E.

AU - Otto, Markus

AU - Engelborghs, Sebastiaan

AU - Herukka, Sanna-Kaisa

AU - Lehmann, Sylvain

AU - Lewczuk, Piotr

AU - Lleó, Alberto

AU - Perret-Liaudet, Armand

AU - Tumani, Hayrettin

AU - Turner, Martin R.

AU - Verbeek, Marcel M.

AU - Wiltfang, Jens

AU - Zetterberg, Henrik

AU - Parnetti, Lucilla

AU - Blennow, Kaj

PY - 2018

Y1 - 2018

N2 - Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer's disease cerebrospinal fluid (CSF) biomarkers, anti-neuromyelitis optica antibodies and blood neurofilament light. We still, however, have a strong need for additional biomarkers and several gaps in their development and implementation should be filled. Examples of such gaps are i) limited knowledge of the causes of neurological diseases, and thus hypotheses about the best biomarkers to detect subclinical stages of these diseases; ii) the limited success translating discoveries obtained by e.g. initial mass spectrometry proteomic low-throughput studies into immunoassays for widespread clinical implementation; iii) lack of interaction among all stakeholders to optimise and adapt study designs throughout the biomarker development process to medical needs, which may change during the long period needed for biomarker development. The Society for CSF Analysis and Clinical Neurochemistry (established in 2015) has been founded as a concerted follow-up of large standardisation projects, including BIOMARKAPD and SOPHIA, and the BioMS-consortium. The main aims of the CSF society are to exchange high level international scientific experience, to facilitate the incorporation of CSF diagnostics into clinical practice and to give advice on inclusion of CSF analysis into clinical guidelines. The society has a broad scope, as its vision is that the gaps in development and implementation of biomarkers are shared among almost all neurological diseases and thus they can benefit from the activities of the society.

AB - Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer's disease cerebrospinal fluid (CSF) biomarkers, anti-neuromyelitis optica antibodies and blood neurofilament light. We still, however, have a strong need for additional biomarkers and several gaps in their development and implementation should be filled. Examples of such gaps are i) limited knowledge of the causes of neurological diseases, and thus hypotheses about the best biomarkers to detect subclinical stages of these diseases; ii) the limited success translating discoveries obtained by e.g. initial mass spectrometry proteomic low-throughput studies into immunoassays for widespread clinical implementation; iii) lack of interaction among all stakeholders to optimise and adapt study designs throughout the biomarker development process to medical needs, which may change during the long period needed for biomarker development. The Society for CSF Analysis and Clinical Neurochemistry (established in 2015) has been founded as a concerted follow-up of large standardisation projects, including BIOMARKAPD and SOPHIA, and the BioMS-consortium. The main aims of the CSF society are to exchange high level international scientific experience, to facilitate the incorporation of CSF diagnostics into clinical practice and to give advice on inclusion of CSF analysis into clinical guidelines. The society has a broad scope, as its vision is that the gaps in development and implementation of biomarkers are shared among almost all neurological diseases and thus they can benefit from the activities of the society.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85043757500&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29544527

U2 - 10.1186/s13195-018-0359-x

DO - 10.1186/s13195-018-0359-x

M3 - Review article

VL - 10

JO - Alzheimer's Research & Therapy

JF - Alzheimer's Research & Therapy

SN - 1758-9193

IS - 1

M1 - 30

ER -